STTK Shattuck Labs, Inc.

BEARISH Impact: 6/10 424B5
Horizon immediate Filed Jun 9, 2026 Processed 5d 13h ago SEC 0001193125-26-264029
Notable filing: 424B5

Price Chart

Loading chart...

Executive Summary

Shattuck Labs filed a preliminary prospectus supplement for an underwritten public offering of common stock and pre-funded warrants, with all key terms (number of shares, offering price, net proceeds) left as placeholders. The filing follows positive Phase 1 data for lead candidate SL-325 and concurrent warrant exercises expected to generate ~$54.9M in gross proceeds. The dilutive offering, while providing additional capital to extend runway into 2029, creates immediate and substantial dilution for new investors.

Actionable Insight

Monitor the final offering terms (size, price) when announced. The massive existing warrant overhang (~86M shares) and this new offering will pressure the stock. Positive Phase 1 data provides some fundamental support, but the dilutive capital raise is the dominant near-term factor.

Key Facts

  • Offering of common stock and pre-funded warrants; all pricing and size details are TBD placeholders
  • Last reported sale price on June 8, 2026 was $3.90 per share
  • Company reported positive Phase 1 data for SL-325 on June 8, 2026
  • Warrant exercises from August 2025 private placement expected to yield ~$54.9M gross proceeds
  • Cash and investments of ~$90.4M as of March 31, 2026; pro forma runway into 2029
  • 75,581,787 shares outstanding as of March 31, 2026; massive overhang from 47.5M common warrants and 38.4M pre-funded warrants
  • Net tangible book value per share as of March 31, 2026 was $1.27; offering will cause immediate and substantial dilution

Financial Impact

Offering size and pricing undisclosed; immediate substantial dilution to new investors; pro forma cash runway extended into 2029

dilutioncash runway

Risk Factors

  • Immediate and substantial dilution to existing and new shareholders
  • Massive overhang from ~86M outstanding warrants and pre-funded warrants
  • No established trading market for pre-funded warrants limits liquidity
  • Broad discretion in use of proceeds may not enhance shareholder value

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (14 analysts)

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
424B5 Filing (Primary)0001193125-26-264029
Document: 0001193125-26-264029-index-headers.html0001193125-26-264029
Document: 0001193125-26-264029-index.html0001193125-26-264029
Document: 0001193125-26-264029.txt0001193125-26-264029
14 reports for STTK
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for STTK — sortable, filterable
Type Now
Jun 11, 2026
3d ago
8-K
BEARISH ★ 6/10
$4.13 awaiting T+1awaiting T+1$4.94 (−19.61%)
Jun 11, 2026
3d ago
Institutional Cluster
BEARISH ★ 4/10
$4.13 awaiting T+1awaiting T+1$4.94 (−19.61%)
Jun 11, 2026
4d ago
424B5
BEARISH ★ 6/10
$4.13 awaiting T+1awaiting T+1$4.94 (−19.61%)
Jun 10, 2026
5d ago
Press Release
BEARISH ★ 6/10
$4.27 awaiting T+1awaiting T+1$4.94 (−15.69%)
Jun 9, 2026
5d ago
424B5
BEARISH ★ 6/10
$4.27 awaiting T+1awaiting T+1$4.94 (−15.69%)
Jun 9, 2026
5d ago
8-K
BULLISH ★ 6/10
$4.27 awaiting T+1awaiting T+1$4.94 (+15.69%)
Jun 2, 2026
12d ago
8-K
NEUTRAL ★ 3/10
$4.75 $4.80▲ +1.05%▲ +0.65%$4.94 (+4.00%)
May 15, 2026
4w ago
Insider Cluster
NEUTRAL ★ 3/10
$6.26 $5.97▼ −4.63%▼ −4.57%$4.94 (−21.09%)
May 12, 2026
4w ago
Insider Cluster
NEUTRAL ★ 3/10
$6.62 $6.75▲ +1.96%▲ +1.39%$4.94 (−25.38%)
May 7, 2026
5w ago
8-K
NEUTRAL ★ 3/10
$6.26 $6.85▲ +9.42%▲ +8.59%$4.94 (−21.09%)
Showing 10 of 14

US Market Status

Market Closed — Opens in 2h 16m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access